Log in to search using one of your social media accounts:


MDS classification is improving in an era of the WHO 2016 criteria of MDS: A population-based analysis among 9159 MDS patients diagnosed in the Netherlands

Conclusion The classification of MDS is improving in the Netherlands. Nevertheless, particular diagnostic and prognostic procedures that are essential for the diagnosis and subsequent treatment decision-making of MDS were not fully utilized in particular patient subsets.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research

Related Links:

Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts, Published online: 20 November 2017; doi:10.1038/s41408-017-0016-9
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
Publication date: Available online 9 November 2017 Source:Seminars in Cancer Biology Author(s): Christian Flotho, Sebastian Sommer, Michael Lübbert Myelodysplastic syndrome (MDS) is a clonal bone marrow disorder, typically of older adults, which is characterized by ineffective hematopoiesis, peripheral blood cytopenias and risk of progression to acute myeloid leukemia. Juvenile myelomonocytic leukemia (JMML) is an aggressive myeloproliferative neoplasm occurring in young children. The common denominator of these malignant myeloid disorders is the limited benefit of conventional chemotherapy and a particular responsiv...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Condition:   Myelodysplastic Syndrome Intervention:   Drug: OPN-305 Sponsors:   Opsona Therapeutics Ltd.;   M.D. Anderson Cancer Center;   Montefiore Medical Center;   H. Lee Moffitt Cancer Center and Research Institute;   New York Presbyterian Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusion This study tentatively suggests that the diagnosis of childhood malignancy follows a seasonal trend in Korea, and has a possible correlation with viral prevalence in several diseases. Further long-term analysis of epidemiological data is needed to explore possible causality.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 1 November 2017 Source:Seminars in Cancer Biology Author(s): Linn Gillberg, Andreas D. Ørskov, Minmin Liu, Laurine B.S. Harsløf, Peter A. Jones, Kirsten Grønbæk Over the past few years it has become clear that vitamin C, as a provider of reduced iron, is an essential factor for the function of epigenetic regulators that initiate the demethylation of DNA and histones. Vitamin C deficiency is rare in the general population, but is frequently observed in patients with cancer. Genes encoding epigenetic regulators are often mutated in cancer, underscoring their cent...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
This article is protected by copyright. All rights reserved.
Source: International Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Article Source Type: research
Elevated serum tryptase values may be found in several conditions, including mastocytosis, myeloproliferative neoplasms, hypereosinophilic disorders, and myelodysplastic syndromes. Increased density of tissue mast cells is correlated with poor prognosis in lung adenocarcinoma as well as melanoma, gastric carcinoma, and breast cancer. While an elevated tryptase has been proposed as a biomarker in several hematologic malignancies including chronic myeloid leukemia, an elevated tryptase has not been previously reported in association with lung adenocarcinoma.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research
WT4869 is a synthetic peptide vaccine derived from the Wilms’ tumor gene 1 (WT1) protein. This phase 1/2 open‐label study evaluated the safety and efficacy of WT4869, and biomarkers for response, in patients with myelodysplastic syndrome. WT4869 (5–1200 μg/dose) was administered intradermally every 2 weeks, according to a 3 + 3 dose‐escalation method in higher‐risk (International Prognostic Scoring System score ≥1.5) or lower‐risk (score
Source: Cancer Science - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research
More News: Cancer | Cancer & Oncology | Epidemiology | Myelodysplastic Syndrome | Netherlands Health